OXPHOS inhibitor IACS010759 suppresses tumor growth by modulating autophagy in esophageal squamous cell carcinoma
Pathology - Research and Practice · 2026
DOI: 10.1016/j.prp.2026.156363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Xiao Han und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China; International Joint Research Laboratory for Regenerative Medicine and Neurofu…. Hauptthemen laut MEDLINE: Autophagy, Oxidative Phosphorylation, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Henan Provincial Science and Technology Research Project.
Abstract (Originalsprache)
Esophageal squamous cell carcinoma (ESCC) is a prevalent and highly malignant digestive tract cancer with poor prognosis. Cancer cells generally exhibit increased glycolytic activity, and it was previously believed that oxidative phosphorylation (OXPHOS) is downregulated in all cancers. However, recent studies have shown increased OXPHOS activity in some tumors, even alongside active glycolysis. This has led to the exploration of targeting elevated OXPHOS as a therapeutic strategy. Despite this, the role of OXPHOS in ESCC tumorigenesis and progression remains unclear. In this study, we found that OXPHOS-related genes are highly expressed in ESCC cell lines and tissues, and this elevated expression correlates with clinical prognosis. The OXPHOS inhibitor IACS-010759 suppressed ESCC cell proliferation, clonogenicity, and migration, while disrupting mitochondrial morphology and function. Furthermore, IACS-010759 inhibited xenograft tumor growth in nude mice. Treatment with IACS-010759 also inhibited autophagy and activated the AKT/mTOR pathway in ESCC cells. The autophagy inducer rapamycin counteracted the inhibitory effects of IACS-010759, indicating that IACS-010759 inhibits ESCC autophagy via AKT/mTOR activation, thereby exerting anti-tumor effects. Interestingly, inhibiting OXPHOS increased glycolytic activity. Combining IACS-010759 with the glycolysis inhibitor 2-DG resulted in a significant synergistic anti-tumor effect in ESCC cells and xenografts. In conclusion, our findings suggest that the OXPHOS pathway may serve as a promising therapeutic target for ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China; International Joint Research Laboratory for Regenerative Medicine and Neurofunctional Repair of Henan Province, China.
- Department of Pharmacology, School of Basic Medicine, Zhengzhou University, Zhengzhou, Henan, China.
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China; International Joint Research Laboratory for Regenerative Medicine and Neurofunctional Repair of Henan Province, China. Electronic address: guowenna…
- School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China; International Joint Research Laboratory for Regenerative Medicine and Neurofunctional Repair of Henan Province, China. Electronic address: zhangyt@…
Förderung
- National Natural Science Foundation of China
- Henan Provincial Science and Technology Research Project
Zitieren
APA
Han, X., Hu, X., Zhu, G., Ma, Y., Li, K., Liu, H., Fan, T., Xu, Y., Guo, W., & Zhang, Y. (2026). OXPHOS inhibitor IACS010759 suppresses tumor growth by modulating autophagy in esophageal squamous cell carcinoma. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2026.156363
Vancouver
Han X, Hu X, Zhu G, Ma Y, Li K, Liu H, et al. OXPHOS inhibitor IACS010759 suppresses tumor growth by modulating autophagy in esophageal squamous cell carcinoma. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2026.156363
BibTeX
@article{Han2026,
author = {Han, Xiao and Hu, Xueyuan and Zhu, Guangzhao and Ma, Yingchao and Li, Kaige and Liu, Hongtao and Fan, Tianli and Xu, Yue and Guo, Wenna and Zhang, Yanting},
title = {OXPHOS inhibitor IACS010759 suppresses tumor growth by modulating autophagy in esophageal squamous cell carcinoma},
journal = {Pathology - Research and Practice},
year = {2026},
doi = {10.1016/j.prp.2026.156363}
}
EUVIMED